Current status of molecular biomarkers in endometrial cancer. - Wikidata - awgldk - TriplyDB

Current status of molecular biomarkers in endometrial cancer.

Current status of molecular biomarkers in endometrial cancer.

http://www.wikidata.org/entity/Q38234228

about

hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers Mediator kinase module and human tumorigenesis Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.Microsatellite polymorphism in the P1 promoter region of the IGF‑1 gene is associated with endometrial cancer Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.Stromal p16 expression is significantly increased in endometrial carcinoma.The role of pathology in the management of patients with endometrial carcinoma.Clinical significance of Sam68 expression in endometrial carcinoma.FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Traditional Approaches to Molecular Genetic Analysis.Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues.The PTENP1 Pseudogene, Unlike the PTEN Gene, Is Methylated in Normal Endometrium, As Well As in Endometrial Hyperplasias and Carcinomas in Middle-Aged and Elderly Females.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

P2860

Q26784422-46036905-8BE0-4A9F-AEAD-4CF30CF6F755 Q26800203-28A6A153-06B5-44C1-BB4F-72C3CCA3D894 Q36053925-9C36182D-C515-4679-BA95-FABBF5E8C825 Q36372293-11BAC716-A73B-4DF2-B161-50FF0EE830B3 Q36931333-09BC5F67-9406-4046-A49B-3208A04DEFE6 Q37225495-EC5BD20C-4CA2-41FD-B414-EE89B914ECA1 Q37706048-1ACD5724-A041-4374-962D-D58501FDA23D Q37706263-00B4D642-D7CA-4E80-A0B1-1D5CEDA89A8E Q38686652-CA3027C2-BA4D-481E-8339-935B2937BA68 Q38887139-2C54622E-25CE-4AA0-A8D4-43CD6238D4E1 Q38897134-3546A66B-0EF5-4C29-903B-635336464AE1 Q39026764-41A6D595-F640-473A-BEBF-963267397DCF Q47120951-C08FF988-835B-4B0C-B6C1-1DCD21FE69B6 Q52715322-91D2FA91-C576-40EA-8781-4021902BEA80 Q57903637-B42875BC-EEF1-4771-945E-BD3B1E151E5B

P2860

Current status of molecular biomarkers in endometrial cancer.

http://www.wikidata.org/entity/Q38234228

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Current status of molecular biomarkers in endometrial cancer.

@en

type

label

Current status of molecular biomarkers in endometrial cancer.

@en

prefLabel

Current status of molecular biomarkers in endometrial cancer.

@en

P1433

Q38234228-87D05180-6718-4418-BD2A-14338DFB6750

P1476

Q38234228-35705DCD-B5A4-44B1-B750-9B7F23206F3D

P2093

Q38234228-5F4DE4D6-8341-4C6D-A7C6-CEABEBD82D0E

Q38234228-6B0F2EE9-E5E1-4553-AE5F-FCC5EF72B67A

P2860

Q38234228-008AC9FB-D0EA-460D-B5EE-F027466DD0F1

Q38234228-02DD92E1-F051-4772-AC97-5197B1B967FE

Q38234228-0333E503-0818-4011-9C54-E76CED93D45B

Q38234228-075B3CFB-A132-4665-B151-6AC3A3A0A9B7

Q38234228-0A34462E-ABE3-4C7F-8752-A0A36D3529A3

Q38234228-1228ECC9-B3BB-4E3B-9C4F-C84E3A6B46EE

Q38234228-129634EF-9E5A-44B9-97F7-A57A29A55B45

Q38234228-1449916A-8525-40A3-9AF0-5E22567E5463

Q38234228-1AEB498A-9845-449F-864E-E14639CD63E6

Q38234228-1DD16B75-F2F5-43DE-AB18-76B0FE84CB0C

P2888

Q38234228-195C0189-B0DB-4338-BCE1-2C07D5E2F273

P304

Q38234228-3418C062-37F0-4CB7-A7A2-453A3C27BCCB

P31

Q38234228-504C991D-5EFD-492D-BAB5-F2B651728160

P3181

Q38234228-4B872E25-0F99-4865-A0EB-5448E77FA9EE

P356

Q38234228-9A902413-0131-4386-B60D-680DAB26F435

P433

Q38234228-0B27B876-2F71-4D6A-994B-C6B7B1FF4F8E

P478

Q38234228-D3DB3C59-D0EA-4254-B1C7-7E29B0478751

P577

Q38234228-D87760D2-012B-4044-94D8-F415AD16AA57

P6179

Q38234228-EF4D9EBD-04D3-43CF-A2B2-0E37C66DAD78

P698

Q38234228-66BF343D-72EB-4CE4-A967-505F50E4B610

P921

Q38234228-D899417A-24B4-4BC4-8ADC-3D4AF70749D1

P3181

P356

S11912-014-0403-3

P1433

Current Oncology Reports

P1476

Current status of molecular biomarkers in endometrial cancer.

@en

P2093

H B Salvesen

http://www.w3.org/2001/XMLSchema#string

H M J Werner

http://www.w3.org/2001/XMLSchema#string

P2860

Intratumor heterogeneity: evolution through space and time

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Integrated genomic characterization of endometrial carcinoma

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

Trastuzumab--mechanism of action and use in clinical practice

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

P2888

s11912-014-0403-3

P304

403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

579

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11912-014-0403-3

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036049372

http://www.w3.org/2001/XMLSchema#string

P698

25064587

http://www.w3.org/2001/XMLSchema#string

P921